China-based Matwings Technology has closed a Series A+ financing round raising over RMB 200 million (USD 29 million). The round was co-led by Kunlun Capital, Yonghua Capital and the Shanghai Engine Fund, with participation from other institutional investors.

Matwings is an AI-driven, full-stack protein R&D platform company. It leverages a proprietary, ultra-large-scale protein sequence database and a general-purpose protein design model to enable precise, industry-oriented design of functional proteins.

The company's core platform integrates its protein design model with AI-powered research agents and automated experimental systems. This end-to-end approach spans the entire R&D workflow, from market analysis and molecular design to process optimisation and scale-up manufacturing. The technology aims to accelerate the development of a wide range of protein-based bioproducts, including innovative therapeutics, agricultural solutions, functional foods and bio-based materials.

PharmCube's MedAlpha® database lists a total of 8 financing events for Matwings. Click here to request a free trial for MedAlpha®.